Correlation Between ALDH2 Gene Polymorphism and Coronary Artery Disease in Patients With Atrial Fibrillation
Cardiovascular Therapeutics · 2026
DOI: 10.1155/cdr/8733628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Bo Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Zigong Third People's Hospital, Zigong, China, www.zgsyy.cn. Hauptthemen laut MEDLINE: Aldehyde Dehydrogenase, Mitochondrial, Atrial Fibrillation, Coronary Artery Disease, Polymorphism, Genetic. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
The objectives of this study is to investigate the correlation between genotype polymorphism of aldehyde dehydrogenase 2 (ALDH2) and coronary artery disease (CAD) in atrial fibrillation patients.
Methods
From November 2020 to December 2021, 80 patients with atrial fibrillation at a medical center in Chengdu were divided into two groups: CAD group ( n = 25) and non‐CAD group ( n = 55). The genotype composition ratio of ALDH2 (mutant‐type/wild‐type), blood biochemical indexes, the proportion of the history of lipid‐lowering drugs and time of taking lipid‐lowering drug were compared between the two groups.
Results
The CAD group showed significantly lower levels of total cholesterol and low‐density lipoprotein cholesterol (LDL‐C) compared with the non‐CAD group ( p < 0.05), and the proportion and time of taking lipid‐lowering drugs in CAD group were significantly increased ( p < 0.05). The frequency of the ALDH2 genotype (mutant‐type/wild‐type) in the CAD group was notably elevated compared with that in the non‐CAD group ( p < 0.05). In patients with atrial fibrillation, the risk of CAD in patients with ALDH2 mutant genotype (GA + AA) was 5.849 times that of ALDH2 wild‐type genotype (GG) (95 % CI = 1.437–23.795, p < 0.05). The area under ROC curve of ALDH2 mutant genotype (GA + AA) was 0.624 (SE = 0.069, 95 % CI : 0.488–0.759). In patients with ALDH2 wild‐type (GG), the levels of total cholesterol and LDL‐C in CAD group were significantly lower than those in non‐CAD group ( p < 0.05). However, in patients with ALDH2 mutation genotype (GA + AA), the proportion of history of lipid‐lowering drugs in CAD group was significantly higher than that in non‐CAD group ( p < 0.05).
Conclusions
The polymorphism of ALDH2 gene is a high risk factor for CAD in patients with atrial fibrillation. The ALDH2 mutation genotype (GA + AA) may reduce the lipid‐lowering efficacy of statins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Zigong Third People's Hospital, Zigong, China, www.zgsyy.cn.
- Department of Cardiology, The General Hospital of Western Theater Command, Chengdu, China.
- Department of Emergency Surgery, Yancheng No.1 People's Hospital, Affiliated Hospital of Medical School, Nanjing University, Yancheng, China, nju.edu.cn.
- Department of Emergency Surgery, The First people's Hospital of Yancheng, Yancheng, China.
- College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China, swjtu.edu.cn.
- Department of Clinical Medicine, Southwest Medical University, Luzhou, China, swmu.edu.cn.
ORCID-Profile: Bo Zheng, Meiling Li, Peng Wang, Jialong Lin, Haifeng Pei, Hao Liu, Xianglin Ye
Zitieren
APA
Zheng, B., Li, M., Wang, P., Lin, J., Pei, H., Liu, H., & Ye, X. (2026). Correlation Between ALDH2 Gene Polymorphism and Coronary Artery Disease in Patients With Atrial Fibrillation. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/8733628
Vancouver
Zheng B, Li M, Wang P, Lin J, Pei H, Liu H, et al. Correlation Between ALDH2 Gene Polymorphism and Coronary Artery Disease in Patients With Atrial Fibrillation. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/8733628
BibTeX
@article{Zheng2026,
author = {Zheng, Bo and Li, Meiling and Wang, Peng and Lin, Jialong and Pei, Haifeng and Liu, Hao and Ye, Xianglin},
title = {Correlation Between ALDH2 Gene Polymorphism and Coronary Artery Disease in Patients With Atrial Fibrillation},
journal = {Cardiovascular Therapeutics},
year = {2026},
doi = {10.1155/cdr/8733628}
}
EUVIMED